(2S)-2-aminopropanoic acid;3,4-dihydropyridine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-aminopropanoic acid;3,4-dihydropyridine
• 化学式: C8H14N2O2
• 分子量: 170.21
• InChiKey: WDMPUTONRZTSDA-WNQIDUERSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.78
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  75.7
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• NEW TOPICAL FORMULATION FOR USE IN ALOPECIA
  申请人：Tomorrowlabs GmbH

  公开号：EP3917525A1

  公开（公告）日：2021-12-08
• [EN] IRON CHELATORS AND USE THEREOF FOR REDUCING TRANSPLANT FAILURE<br/>[FR] CHÉLATEURS DU FER ET LEUR UTILISATION POUR LA RÉDUCTION D'ÉCHEC DE TRANSPLANTATION
  申请人：UNIV LELAND STANFORD JUNIOR

  公开号：WO2014036414A2

  公开（公告）日：2014-03-06

  Formulations and methods are provided for improving the function, i.e. clinical outcome, of solid organ transplants. Lung transplantation is of particular interest. In the methods of the invention, a nanoparticle formulation comprising an effective dose of an iron chelator active agent in nanoparticle form, including without limitation, deferoxamine (DFO), deferasirox (DFX), and deferiprone (DFP), etc. suspended in a carrier compatible with the tissue of interest, is topically applied to the surface of tissues at the site of anastomosis. The nanoparticles are comprised of the active agent and a pharmaceutically acceptable stabilizer.
• [EN] IRON CHELATORS AND USE THEREOF FOR REDUCING TRANSPLANT FAILURE DURING REJECTION EPISODES<br/>[FR] CHÉLATEURS DU FER ET LEUR UTILISATION POUR RÉDUIRE L'ÉCHEC DE GREFFE PENDANT DES ÉPISODES DE REJET
  申请人：UNIV LELAND STANFORD JUNIOR

  公开号：WO2014100233A1

  公开（公告）日：2014-06-26

  Formulations and methods are provided for improving the function, i.e. clinical outcome, of solid organ transplants. Lung transplantation is of particular interest. In the methods of the invention, a nanoparticle formulation comprising an effective dose of an iron chelator active agent in nanoparticle form, including without limitation, deferoxamine (DFO), deferasirox (DFX), and deferiprone (DFP), etc. is topically applied to the surface of tissues during episodes of graft rejection.
• [EN] NEW TOPICAL FORMULATION FOR USE IN ALOPECIA<br/>[FR] NOUVELLE FORMULATION TOPIQUE DESTINÉE À ÊTRE UTILISÉE DANS L'ALOPÉCIE
  申请人：TOMORROWLABS GMBH

  公开号：WO2020157064A1

  公开（公告）日：2020-08-06

  The invention relates to a composition comprising a HIF-la activity potentiating agent for use in a method of preventing or treating hair loss, wherein the HIF-la activity potentiating agent is an iron chelator, preferably Deferiprone. The invention further relates to a composition for topical application, comprising a HIF-la activity potentiating agent that is an iron chelator. Furthermore, the invention relates to a method for cosmetic treatment or prevention of hair loss, comprising topical application of a composition comprising a HIF-la activity potentiating agent that is an iron chelator to an area of skin.
• [EN] DERMAL FILLER WITH HIF-1α ACTIVITY MODULATORS<br/>[FR] IMPLANT DERMIQUE À MODULATEURS DE L'ACTIVITÉ DE HIF-1α
  申请人：THOR DOMINIK

  公开号：WO2021259471A1

  公开（公告）日：2021-12-30

  The present invention provides a composition comprising hyaluronic acid (HA) and a HIF-1α activity potentiating agent (HPA), wherein the composition is in a form selected from the group consisting of a solution for injection, a suspension for injection, an emulsion for injection, and a gel for injection. In addition, the present invention provides said composition for use in medicine, in particular in a method of treatment of a condition selected from the group consisting of stress urinary incontinence, vesicoureteral reflux, vocal fold insufficiency, and vocal fold medialization. The invention further provides a method for replacing a biological tissue or increasing the volume of a biological tissue for cosmetic or therapeutic purposes, a method of treatment and a method of cosmetic treatment comprising administration of said composition. Furthermore, the invention provides the use of said composition for cosmetic applications, a kit comprising HA and a HPA, in particular DFO, and a method for preparing an injectable dermal filler, comprising the steps of: (a) providing a HA gel, (b) providing a HPA, in particular DFO, (c) mixing the HA gel and the HPA.